Research programme: reactive aldehyde species inhibitors - Aldeyra Therapeutics
Alternative Names: RASP inhibitors - Aldeyra TherapeuticsLatest Information Update: 22 Mar 2022
At a glance
- Originator Aldeyra Therapeutics
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Aldehyde inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Retinal disorders
Most Recent Events
- 31 Dec 2021 Preclinical trials in Autoimmune disorders in USA (unspecified route) (Form 10K, Aldeyra Therapeutics, December 2021)
- 31 Dec 2021 Aldeyra Therapeutics plans to submit IND application to the US FDA for Retinal disorders and Autoimmune disorders in the year 2022
- 07 Sep 2021 Preclinical trials in Retinal disorders in USA (Intravitreous) (Aldeyra Therapeutics pipeline, September 2021)